Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drugs' Net Price Only Growing Modestly, Express Scripts Finds

Executive Summary

Overall unit cost in commercial insurance market was up only 2.5% in 2016 despite 11% list increase for brands, PBM's Drug Trend Report concludes; findings could be counterpoint to public and policymaker concerns with drug pricing.

You may also be interested in...



What's At Stake: Biopharma Profit Growth Reliant On Price Increases

Price increases generated 100% of net US earnings growth at major biopharma firms in 2016, according to investment analyst report assessing threat of continued pricing pressure.

MS Drug Prices Far Exceed Value Thresholds, Even At Current Discounts – ICER Report

List pricing for Biogen’s Tecfidera and Novartis’ Gilenya would need to be discounted 47% and 50%, respectively, for them to be considered good values, ICER concludes in a new report. But three products come in under ICER's thresholds.

Pricing By Indication Takes Hold, Despite Hurdles

Indication-based drug pricing is one mechanism for pegging price to value. It will be tough to implement in the US without systemic change, but PBMs have plenty of incentives to make it work.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS119992

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel